PolyPid Reports Q3 2026 Financial Results and D-PLEX100 Regulatory Progress
PolyPid Ltd. (PYPD) reported improved financial results for the third quarter of 2026, highlighted by a reduction in net loss to $5.8 million ($0.24 per share) compared to $7.5 million in the prior year period. The company's cash position strengthened to $15.5 million as of September 30, bolstered by a recent $15 million milestone payment from Azurity Pharmaceuticals following NDA acceptance. The company is approaching a critical regulatory milestone with a PDUFA goal date of November 28, 2026, for its lead candidate, D-PLEX100. Supported by Azurity's commercial infrastructure, PolyPid is preparing for an anticipated U.S. launch in early 2027. Additionally, the company has regained full European commercialization rights for D-PLEX100 and continues to advance its pipeline with PD01B.
Tickers: $PYPD
Topics: Cash runway Net loss reduction Phase III clinical trial results Quarterly earnings Surgical site infections